Saxenda (liraglutide) is a prescription drug that’s used for weight management. Saxenda’s cost may depend on factors such as whether you have health insurance and the pharmacy you use. Saxenda is used ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

Saxenda Approved for Weight Management The FDA has approved Saxenda (liraglutide [rDNA origin]) injection for chronic weight management. Saxenda is the first glucagon-like peptide-1 (GLP-1) receptor ...

European regulators have recommended an update to the label of Novo Nordisk’s weight loss drug, Saxenda, to include information about the active ingredient’s ability to reduce cardiovascular risk.

A new injectable drug, aimed at helping obese and seriously overweight people who have other weight-related health conditions, has proven effective in a new round of testing. The drug, called ...

COPENHAGEN (Reuters) -Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity ...

Novo Nordisk’s liraglutide is one drug with two names. With last week’s approval of Saxenda, Novo is planning to unveil the second of the two brands in the liraglutide franchise, this one labeled for ...

Novo Nordisk’s obesity drug Saxenda, which shares the ingredient liraglutide with the company's diabetes treatment Victoza, has been shown to reduce appetite. The drug is an analog of naturally ...

Novo Nordisk's injectable 3-mg liraglutide (Saxenda) was approved for chronic weight management in teens with obesity, the FDA announced late Friday. The GLP-1 receptor agonist, which was first ...

Novo Nordisk’s (NVO) anti-obesity drug portfolio includes Saxenda. For details on the drug and the obesity care market, please refer to Novo Nordisk Aims to Establish Strong Presence in Obesity Market ...